aidsmap news story

Merck’s investigational once-monthly PrEP pill could be manufactured and sold profitably for around $3 per person per year, making it the cheapest HIV prevention drug ever brought to market, the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro heard. But the licensing deal announced by the company days earlier leaves out most of Latin America, including countries hosting the drug’s own phase III trials.

MK-8527, now known as alimatravir, belongs to a new class of drugs called nucleoside reverse transcriptase translocation inhibitors. It is taken as a single tablet once a month at a dose of 11 mg, compared to 500 mg a day for oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).

Read the full news story here.View all aidsmap reports from AIDS 2026